The Antidepressant Epidemic Nobody Is Talking About: Perimenopausal Women and the Brain Chemistry Shift

By Krystle Alves | Naturopath, Nutritionist & Yoga Therapist | B.HSc, Adv. Dip. Naturopathy

The fastest-growing demographic being prescribed antidepressants in Australia is women in their perimenopausal transition. Not adolescents. Not people with diagnosed psychiatric illness. Women in their forties, often in the most demanding decade of their lives professionally and personally, presenting to their GP with low mood, anxiety, emotional volatility, sleep disruption, and a sense that they are no longer themselves, and leaving with a prescription for an SSRI.

This is not an argument against antidepressants. Let me be very clear about that upfront. If you are at risk of harming yourself or others, antidepressants may be a vital starting point to stabilise things while you're picking through other elements of your health. That is a legitimate and sometimes life-saving use of these medications, and it should not be dismissed.

But antidepressants were designed as short-term interventions, not long-term solutions. They were developed to address a deficit in monoamine neurotransmitter activity, primarily serotonin, in the context of clinical depression. What they were not designed for, and what the prescribing data suggests they are increasingly being used for, is the management of a complex neuroendocrine transition in which the brain's entire neurochemical environment is being reorganised by shifting hormones. Treating that with a single-mechanism pharmaceutical while the underlying hormonal, nutritional, and metabolic drivers go unaddressed is not treatment. It is suppression. And suppression without investigation means the transition continues, the drivers compound, and women emerge from perimenopause on a medication that may never have been their answer.

What follows is what I wish every woman in this transition had been told before she left that GP appointment with a prescription.

Having been a naturopath for over 18 years, one of the things that saddens me the most is seeing women in this age group come into my clinic feeling like they’ve done something terribly wrong; asking me how they’ve been so emotionally and mentally stable all their life and now they’ve been labelled with a mental illness and sent away with an antidepressant medication. Having no idea how they got here!

I delve into some complex and inter-related genetics and biochemistry in this post, not to overwhelm you but to show you that there is a complex dynamic situation unfolding in your brain during perimenopause….If nothing else, I want this blog post to show you that you’ve done nothing wrong- you’re simply living in a system that hasn’t yet bridged the gap in understanding how perimenopause is impacting your brain- and unfortunately you’re paying the price for that.

When I’ve taken the time to explain this to my patients in clinic, they often end up in tears- tears of relief, finally understanding that they aren’t merely ‘struggling mentally’ they are struggling to get the support they need to navigate the wild ride that is perimenopause.

What Perimenopause Actually Does to the Brain

Perimenopause is not simply the years before periods stop. It is a neurological event as much as a reproductive one. The brain is exquisitely sensitive to estrogen, and the chaotic hormonal fluctuations of perimenopause, in which estrogen surges and crashes unpredictably over months to years before ultimately declining, produce measurable changes in neurotransmitter function, brain structure, and cognitive processing.

To understand why, you need to understand the relationship between estrogen and the brain's key chemical systems.

Estrogen and Serotonin

Estrogen and serotonin are deeply interdependent. Estrogen upregulates the activity of tryptophan hydroxylase, the enzyme that converts tryptophan (from dietary protein) into 5-hydroxytryptophan (5-HTP) and then into serotonin. It increases the density and sensitivity of serotonin receptors in the brain, particularly in the prefrontal cortex and limbic system. It reduces the activity of the serotonin reuptake transporter (the same transporter that SSRIs block), effectively increasing the availability of serotonin at the synapse.

When estrogen is stable and adequate, serotonin signalling is well-supported. When estrogen fluctuates wildly, as it does in perimenopause, serotonin signalling fluctuates with it. This is not a coincidence or a metaphor. It is a direct biochemical relationship, and the mood instability that characterises perimenopause is, in significant part, a reflection of this serotonin dysregulation driven by estrogen volatility.

The point missed by prescribing an SSRI here is that SSRIs address the serotonin reuptake step while leaving the upstream hormonal driver entirely untouched. In some women, this is sufficient to reduce symptoms. In many, the hormonal fluctuations continue to overwhelm the serotonergic system regardless of reuptake inhibition.

Progesterone, Allopregnanolone, and GABA

If serotonin is the daylight system of mood regulation, GABA is the dimmer switch: the brain's primary inhibitory neurotransmitter that produces calm, reduces anxiety, promotes sleep, and buffers the nervous system against overstimulation.

Progesterone is converted in the brain to allopregnanolone, a potent neurosteroid that acts as a positive allosteric modulator of GABA-A receptors. In plain terms: allopregnanolone makes GABA receptors more sensitive and more responsive. It is the mechanism by which adequate progesterone produces the calming, sleep-supportive, and anxiolytic effects many women associate with the second half of their cycle.

Progesterone declines before estrogen in perimenopause. It declines steeply, it declines early, and its decline is one of the earliest and most destabilising neurochemical changes of the transition. As progesterone falls, allopregnanolone falls with it. GABA receptor sensitivity decreases. The brain's natural anxiety-buffer shrinks. The result is the onset of anxiety, insomnia, and emotional reactivity that is frequently the first perimenopausal symptom women notice, often years before periods become irregular or obvious hot flushes begin.

This is not a psychiatric condition. It is a GABA deficit, driven by a progesterone deficit. An SSRI does not address GABA. It does not restore allopregnanolone. It addresses serotonin, leaving the primary neurochemical driver of this early perimenopausal anxiety entirely unmanaged.

Estrogen and Dopamine

Dopamine drives motivation, reward, focused attention, and the capacity for pleasure. It is the neurochemical of agency and drive. Estrogen modulates dopaminergic activity in the prefrontal cortex and mesolimbic system, and estrogen withdrawal (as occurs in the sharp drops of perimenopausal hormonal cycling) reduces dopamine receptor sensitivity and dopaminergic tone.

The clinical consequence is the symptom often described as anhedonia: an absence of pleasure, motivation, or interest that is not sadness but a kind of blankness. The loss of the feeling that anything is worth doing. The inability to look forward to things that previously produced anticipation. This is dopaminergic, not purely serotonergic, and it is directly hormonal in origin during perimenopause. Yet it is the symptom most reliably interpreted as depression and medicated accordingly.

Estrogen, Noradrenaline, and the Locus Coeruleus

The locus coeruleus is the brain's principal noradrenergic nucleus: the primary source of noradrenaline (norepinephrine) throughout the brain. It regulates arousal, vigilance, attention, and the fight-or-flight response. Estrogen receptors are densely expressed in the locus coeruleus, and estrogen normally provides tonic inhibitory input to this system, keeping arousal regulated and preventing excessive noradrenergic firing.

When estrogen drops sharply, as it does repeatedly in perimenopause, the locus coeruleus loses this inhibitory input and fires more readily and more intensely. This is the neurological mechanism behind hot flushes: a burst of noradrenergic activity that triggers vasodilation and the thermogenic cascade. It is also the mechanism behind the anxiety, hypervigilance, and exaggerated stress responses that characterise perimenopausal mood disruption. The nervous system is more reactive because its chemical regulation has been disrupted at the source.

Histamine: The Neurotransmitter Nobody Mentioned

Most people think of histamine as an allergy mediator: the molecule that makes eyes water and noses run during hay fever season. This is one of histamine's roles. What is rarely explained is that histamine is also a significant neurotransmitter in its own right, and that a substantial proportion of women entering perimenopause find their histamine tolerance deteriorating in ways that directly and measurably affect the brain.

Histaminergic neurons originate primarily in the tuberomammillary nucleus of the hypothalamus and project widely throughout the brain. Histamine acting on H1 receptors promotes wakefulness, arousal, and attention: it is one of the brain's principal wake-promoting signals, which is why older antihistamines that cross the blood-brain barrier cause drowsiness. Via H2 receptors, histamine modulates gastric acid secretion and certain aspects of cardiac function. Via H3 receptors, which are predominantly presynaptic in the brain, it regulates the release of other neurotransmitters, including serotonin, dopamine, GABA, and noradrenaline. Histamine is not a peripheral irritant that occasionally wanders into the brain. It is a central neuromodulator that shapes the availability and activity of the very same neurotransmitter systems already under hormonal pressure in perimenopause.

The relationship between histamine and estrogen is bidirectional, and in perimenopause this bidirectionality becomes a significant clinical problem. Estrogen stimulates mast cells, one of the body's primary histamine stores, to degranulate and release histamine. This means that the estrogen surges of early perimenopause, before the eventual decline, actively drive histamine release. At the same time, histamine stimulates the ovaries to produce more estrogen, creating a feedback loop that, in an already hormonally volatile transition, can amplify both estrogen fluctuation and histamine burden simultaneously.

Progesterone operates on the other side of this equation. Progesterone upregulates the activity of diamine oxidase (DAO), the primary enzyme responsible for degrading histamine in the gut and body. As progesterone declines early in perimenopause, DAO activity falls. The enzyme clearing histamine becomes less active precisely when estrogen-driven histamine release is increasing. The net effect, for women who are already constitutionally limited in their histamine clearance capacity, is an escalating histamine load that the body cannot efficiently process.

In the brain, excess histamine produces a recognisable cluster of symptoms: wakefulness and sleep fragmentation (histamine's H1-mediated arousal function persisting through the night), anxiety and a heightened startle response, difficulty winding down, headaches and migraines (the trigeminovascular connection to histamine is well documented), and a general sense of irritability and emotional reactivity that sits on top of the other neurochemical disruptions of the transition. For women who experience flushing, heart palpitations, worsening anxiety in the luteal phase, or symptoms that flare with wine, aged cheese, fermented foods, or leftover protein, the histamine picture is almost certainly a contributing factor.

The genetic dimension adds further specificity. The AOC1 gene encodes the DAO enzyme: slow-activity AOC1 variants reduce the body's capacity to break down dietary and endogenous histamine. The HNMT gene encodes histamine N-methyltransferase, the intracellular enzyme that degrades histamine within cells, including neurons. Slow HNMT variants impair central histamine clearance specifically, prolonging the neuroactive effects of histamine in the brain. Both genes are assessed in the genetic screening I run clinically, and the combination of slow AOC1, slow HNMT, and the falling progesterone and DAO activity of perimenopause creates a cumulative histamine burden that, if unrecognised, produces a significant neurological and mood symptom picture that bears almost no resemblance to classic allergy and is therefore almost never traced to its actual source.

It is worth noting the methylation connection here, because it closes a loop with the other systems described in this article. Both HNMT function and DAO function depend, in part, on adequate SAMe availability. SAMe, the primary methyl donor, is produced through the methylation cycle that requires adequate B12 and active folate, and is reduced by MTHFR variants and functional B12 deficiency. A woman entering perimenopause with MTHFR variants, TCN2 variants, falling progesterone, estrogen-driven mast cell activation, and slow AOC1 or HNMT genotypes is navigating a histamine problem that has neurological, hormonal, genetic, and nutritional drivers simultaneously. An antihistamine addresses one symptom at one receptor. Understanding the architecture is what makes resolution possible.

The Brain Flush: A Clinical Phenomenon Nobody Is Naming

One of the things I discuss regularly with women in perimenopause is something I call the brain flush. It is something many of them have never heard named before, and the relief of having it named and explained is, for many, as significant as any clinical intervention.

The brain flush is a sudden, overwhelming feeling of dread or doom. It arrives without external trigger. There is nothing happening in life to account for it. No bad news, no identifiable stressor, no build-up. It descends, fully formed, and for anywhere from seconds to minutes the sense of something being catastrophically wrong is total. And then it lifts. As suddenly as it arrived, it is gone, and nothing external has changed.

This is the emotional equivalent of a hot flush, and it operates through the same neurological mechanism.

When estrogen drops sharply, the locus coeruleus fires a burst of noradrenergic activity. In a hot flush, this burst activates the thermoregulatory centres and produces the vasodilatory heat response. In the brain flush, the same noradrenergic burst activates the limbic system and the amygdala, the brain's threat-detection and emotional processing centres, producing an overwhelming affective experience of dread or doom without any corresponding external threat.

Like a hot flush, it is a wave. It crests and it recedes. The limbic activation settles, the amygdala returns to baseline, and the feeling dissipates. It is not depression. It is not anxiety disorder. It is a paroxysmal neuroendocrine event, and it is extraordinarily distressing for the women who experience it, particularly when nobody has told them it is possible and they have been left to interpret it as evidence that something is seriously wrong with their mental health.

In my clinical experience, the brain flush is one of the most consistently underreported, underrecognised, and completely unexplained perimenopausal phenomena. Many women do not mention it to their GP because they cannot explain it in a way that does not sound alarming. Some have been told they are having panic attacks. Some have been put on SSRIs or benzodiazepines. Very few have been told: this is a neuroendocrine event. This is your locus coeruleus responding to estrogen withdrawal. This is not your mental health failing. This is your hormones.

Why This Is Not Being Investigated or Explained

The gap here is not malicious. It is structural and educational.

Perimenopause is not a focus of conventional medical training in the depth it deserves. GP appointments are time-constrained. The diagnostic tools used to assess perimenopausal status (FSH, LH, and estradiol) are of limited utility in the early transition because hormones fluctuate so dramatically day to day that a single blood draw tells you almost nothing. Women presenting with mood symptoms in their forties are statistically more likely to receive a mental health assessment and a prescription than a detailed hormonal, neurological, and metabolic workup.

The hormonal drivers of perimenopausal mood disruption have not historically been well understood outside specialist reproductive psychiatry and functional medicine. The relationship between allopregnanolone and GABA, the estrogen-serotonin axis, and the noradrenergic mechanism of both hot flushes and brain flushes are areas of active research that have not yet meaningfully reached the average GP consulting room. Women are living the consequences of this educational gap, often for years.

And because antidepressants do provide some symptomatic relief in some women (partly through serotonergic effects, partly through the secondary anxiolytic effects of some SNRIs that also act on noradrenaline), they are not without any benefit. But benefit without explanation is still a failure of care. A woman who feels marginally better on an SSRI but has never been told why her brain chemistry changed, what the hormonal architecture of her transition looks like, or what is driving her specific symptom profile has not been adequately treated. She has been sedated.

The Genetic Dimension: Why Some Women Are More Vulnerable

Not all women in perimenopause develop significant mood disruption. The difference between those who transition relatively smoothly and those who find it genuinely destabilising is partly hormonal, partly circumstantial, and significantly genetic. In my clinical work, genetic screening is a core component of understanding a patient's perimenopause presentation and predicting and managing their risk.

COMT (Catechol-O-Methyltransferase). COMT is the enzyme responsible for clearing catecholamines: dopamine, adrenaline, and noradrenaline. Women with the slow COMT variant (Met/Met genotype) clear these neurotransmitters more slowly. Under normal hormonal conditions, this can be an advantage: more sustained dopamine in the prefrontal cortex supports focus and working memory. In perimenopause, however, when estrogen further slows COMT activity (estrogen inhibits COMT enzymatically), slow COMT carriers can accumulate catecholamines to a degree that drives anxiety, rumination, hypervigilance, and difficulty downregulating the stress response. The brain flush in COMT Met/Met women tends to be more intense, more prolonged, and more destabilising. Knowing this genotype changes how we approach nutritional support for neurotransmitter clearance.

MTHFR (Methylenetetrahydrofolate Reductase). MTHFR variants impair the methylation cycle, which is required for the synthesis of SAMe (S-adenosylmethionine), the primary methyl donor for neurotransmitter production. Serotonin, dopamine, noradrenaline, and melatonin all require methylation steps in their synthesis pathways. MTHFR-impaired women enter perimenopause with a reduced capacity to produce and clear neurotransmitters, elevated homocysteine (which is independently neurotoxic), and a narrower neurochemical reserve. When estrogen withdrawal begins stripping the scaffolding from their serotonergic and dopaminergic systems, there is less capacity to compensate. Depression and anxiety in MTHFR-impaired perimenopausal women frequently respond poorly to SSRIs because the methylation deficit driving the neurotransmitter insufficiency remains unaddressed.

SLC6A4 (Serotonin Transporter Gene, 5-HTTLPR). The short allele variant of the serotonin transporter gene reduces transporter expression and serotonin reuptake efficiency. Women with the short/short genotype are constitutionally more sensitive to environmental stressors and to hormonal fluctuations that affect serotonin signalling. Research has specifically examined 5-HTTLPR in perimenopausal mood disorders and found that short allele carriers show greater depressive symptom severity during the transition, and that their serotonergic system is more vulnerable to the estrogen withdrawal that characterises perimenopause. These are the women most likely to experience rapid mood deterioration with sharp hormonal drops, and most likely to require targeted support for serotonin metabolism rather than generic antidepressant prescribing.

MAO-A (Monoamine Oxidase A). MAO-A degrades serotonin, dopamine, and noradrenaline. High-activity MAO-A variants clear these neurotransmitters rapidly, creating a constitutionally lower monoamine tone. In the context of perimenopause, where hormonal withdrawal is already reducing neurotransmitter synthesis, high-activity MAO-A carriers have less capacity to sustain adequate serotonin and dopamine levels. They are more prone to depression, lower energy, and anhedonia, and they are more sensitive to the dietary and nutritional factors that support neurotransmitter synthesis (B6, tryptophan, tyrosine, folate).

BDNF Val66Met. Brain-derived neurotrophic factor (BDNF) is the brain's primary growth and maintenance factor: it supports neuroplasticity, synaptic function, and the brain's capacity to adapt. Estrogen stimulates BDNF production, which is one reason estrogen is neuroprotective. As estrogen declines in perimenopause, BDNF falls. Women with the Val66Met BDNF variant have constitutionally reduced BDNF secretion, making them more vulnerable to the neuroplasticity deficits, cognitive changes, and depression associated with declining estrogen. Low BDNF is one of the most consistent neurobiological findings in depression, and its role in perimenopausal mood disorder is significant and underappreciated.

ESR1/ESR2 (Estrogen Receptor Variants). Variants in estrogen receptor genes affect how sensitively the brain responds to estrogen. Women with certain ESR1 variants show exaggerated neurological responses to estrogen fluctuation, experiencing more severe mood, cognitive, and vasomotor symptoms with the same degree of hormonal change as women without these variants. In effect, the hormonal signal is the same but the receptor's sensitivity amplifies the response.

Taken together, these genetic factors do not determine outcome. They describe susceptibility: the terrain on which perimenopause unfolds, and the specific biological vulnerabilities that targeted intervention can address. This is why genetic screening, for me, is not optional in perimenopausal presentations. It is foundational.

Nutrient Deficiencies That Accelerate the Mood Decline

The brain's neurochemistry does not operate in a vacuum. Every neurotransmitter synthesis pathway has nutritional rate-limiting steps, and deficiencies in the relevant nutrients during perimenopause compound the hormonal disruption already underway.

Magnesium is required as a cofactor for over 300 enzymatic reactions in the body, including the synthesis of serotonin and the regulation of GABA-A receptor function. It also modulates the HPA axis, reducing cortisol output and supporting adrenal recovery. Magnesium is depleted by chronic stress (cortisol promotes urinary magnesium excretion), by alcohol, by high sugar intake, and by certain medications including PPIs. Women in perimenopause, who are frequently under significant physical and psychological stress, are among the most magnesium-depleted populations. Low magnesium contributes directly to anxiety, insomnia, muscle tension, and low mood through its effects on GABA and serotonin signalling.

Vitamin B6 (Pyridoxine) is the cofactor required for the conversion of 5-HTP to serotonin and of L-DOPA to dopamine. Without adequate B6, amino acid precursors accumulate but are not efficiently converted to active neurotransmitters. B6 is also required for the synthesis of GABA from glutamate. Deficiency of B6 is associated with depression, anxiety, and PMS-type symptoms even outside the perimenopausal context, and requirements increase during the hormonal shifts of this transition. B6 deficiency is common and frequently overlooked in standard blood panels, which rarely include it.

Folate (as 5-MTHF) is required upstream in the methylation cycle that produces SAMe. As described in the MTHFR section above, inadequate active folate reduces SAMe availability and therefore impairs synthesis of serotonin, dopamine, noradrenaline, and melatonin. Low folate is independently associated with depression, poor antidepressant response, and cognitive decline. In perimenopausal women with MTHFR variants, ensuring adequate active folate (5-methyltetrahydrofolate, not folic acid, which requires conversion) is a prerequisite for supporting neurotransmitter function.

Vitamin B12 (as Methylcobalamin) works in tandem with folate in the methylation cycle. B12 deficiency reduces SAMe, elevates homocysteine, impairs myelin synthesis, and is associated with depression and cognitive decline. As discussed in detail in the companion article on the TCN2 gene on this site, standard serum B12 testing misses cellular B12 deficiency in women with TCN2 variants, meaning a "normal" B12 result does not rule out functionally inadequate B12 at the neurological level.

Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Iron deficiency impairs dopamine production before it produces the anaemia visible on a standard blood panel. The result is the fatigue, low motivation, cognitive slowing, and anhedonia of iron deficiency that precedes the haematological changes. Many perimenopausal women experience iron depletion from years of heavy or prolonged periods. The mood consequences of iron deficiency are frequently attributed to depression or hormonal changes while the iron picture is managed only from a haematological perspective.

Zinc is a cofactor for serotonin synthesis and is required for BDNF function. Low zinc is associated with depression and with reduced effectiveness of antidepressant medication. Zinc is depleted by chronic stress, by the inflammatory state that often accompanies gut dysbiosis, and by the insulin resistance that increases during perimenopause.

Vitamin D functions as a hormone and a neurotrophic factor as much as a vitamin. Vitamin D receptors are present throughout the brain, and vitamin D directly activates the gene that encodes tryptophan hydroxylase 2 (the brain-specific enzyme for serotonin synthesis). Low vitamin D reduces serotonin production in the brain independently of all other factors. It also reduces dopamine synthesis and BDNF expression. Vitamin D deficiency is extraordinarily common even in sun-exposed populations like Australia, because the melanin content of skin, sunscreen use, time of day, and individual metabolic differences all affect synthesis. In perimenopausal women, where serotonin and BDNF are already under hormonal pressure, vitamin D deficiency removes a critical additional support.

Omega-3 Fatty Acids (EPA and DHA) are structural components of neuronal membranes and critical to serotonin receptor function. EPA specifically reduces neuroinflammation and supports serotonergic signalling. DHA is the dominant structural fat in the brain. Deficiency of EPA and DHA is associated with depression, anxiety, and cognitive decline across multiple large-scale studies. In perimenopause, where neuroinflammation is increased by fluctuating estrogen and by the insulin resistance discussed below, adequate omega-3 status provides anti-inflammatory support at the neurological level that no pharmaceutical antidepressant replicates.

Insulin Resistance, the Perimenopausal Brain, and the Mood Connection

This section deserves particular attention, because insulin resistance in perimenopause is one of the most significant, most overlooked, and most consequential drivers of mood, cognitive, and energy disruption, and it is rarely investigated in women presenting with perimenopausal symptoms.

Why Insulin Resistance Increases in Perimenopause

Estrogen is insulin-sensitising. It promotes glucose uptake in skeletal muscle, modulates adipose tissue distribution (favouring subcutaneous over visceral fat), and reduces hepatic glucose production. When estrogen declines and fluctuates in perimenopause, its insulin-sensitising effects are lost. Simultaneously, cortisol, which is frequently elevated in the HPA-dysregulated state that accompanies perimenopause (discussed in detail in the companion articles on the HPA axis and cortisol awakening response), promotes gluconeogenesis and reduces insulin receptor sensitivity in peripheral tissues.

The result is that many women in perimenopause develop insulin resistance, or see a pre-existing mild insulin resistance worsen significantly, in the absence of any change in diet or lifestyle. Weight accumulates around the abdomen despite unchanged eating habits. Blood glucose becomes less stable. Fasting insulin rises while fasting glucose remains "normal" and HbA1c stays within reference range. Standard testing, which focuses on glucose, catches this too late. Fasting insulin and the HOMA-IR index (which calculates insulin resistance from fasting glucose and insulin) are the appropriate early-detection tools, and they are rarely ordered proactively.

The Brain Is an Insulin-Sensitive Organ

The connection between insulin resistance and brain function is now one of the most rapidly developing areas of neuroscience. The brain accounts for approximately 20 percent of the body's total glucose consumption despite representing only 2 percent of body weight. Neurons are highly dependent on glucose, and the transport of glucose into neurons is, in significant part, insulin-dependent.

When the brain becomes insulin-resistant (a phenomenon increasingly described as a component of Alzheimer's disease pathology, leading to the concept of "type 3 diabetes" in some research contexts), neuronal glucose uptake is impaired. Neurons are literally less able to generate the energy they need to function. The cognitive consequences include brain fog, difficulty with word retrieval, memory lapses, slowed processing, and poor concentration: exactly the cognitive symptoms that perimenopausal women report and that are frequently attributed to "hormones" without any further investigation of the metabolic mechanism.

Insulin Resistance, Mood, and the Inflammatory Link

The mood consequences of insulin resistance operate through several overlapping mechanisms.

Glucose instability drives cortisol spikes. When blood glucose falls, the adrenal glands release cortisol to stimulate gluconeogenesis and restore glucose levels. In insulin-resistant, glucose-unstable women, these cortisol spikes are frequent, dysregulated, and cumulative. Each spike adds to the HPA axis burden, contributes to the anxiety and reactivity that characterises HPA dysregulation, and depletes the adrenal reserve over time.

Visceral adiposity, which increases with perimenopausal insulin resistance, is metabolically active tissue. Visceral fat produces adipokines including leptin, resistin, and inflammatory cytokines (TNF-alpha, IL-6) that cross the blood-brain barrier and drive neuroinflammation. Neuroinflammation degrades neurotransmitter function: inflammatory cytokines activate the enzyme indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan away from the serotonin synthesis pathway and toward the kynurenine pathway, producing inflammatory metabolites instead of serotonin. This is the neuroinflammatory mechanism of depression, and it is driven by the metabolic consequences of insulin resistance in a way that SSRIs do not address.

Insulin resistance also impairs BDNF signalling. Insulin and BDNF share overlapping receptor pathways in the brain, and insulin resistance at the neuronal level reduces BDNF receptor sensitivity. BDNF, as described earlier, is already under pressure from declining estrogen. The combined effect of falling estrogen and insulin resistance on BDNF is a significant driver of cognitive decline and depression risk in this stage of life.

What Adequate Investigation Looks Like

Insulin resistance in perimenopausal women is not complex to assess. What it requires is ordering the right tests. Fasting insulin alongside fasting glucose, calculated as HOMA-IR, gives an early picture of insulin sensitivity before glucose or HbA1c have shifted out of range. A full lipid panel with triglycerides and HDL (the metabolic syndrome markers) adds context. Inflammatory markers including high-sensitivity CRP and ferritin provide evidence of the systemic inflammatory burden. These are not exotic investigations. They are basic metabolic assessments that are simply not routinely ordered in women presenting with perimenopausal mood symptoms, because the connection between insulin resistance and perimenopausal mental health has not yet filtered into mainstream clinical practice.

What Comprehensive Assessment Actually Looks Like

The perimenopausal women I work with clinically typically arrive having already been through multiple conventional touchpoints: a GP who offered antidepressants, a psychiatrist who confirmed the depression diagnosis, perhaps a gynaecologist who offered HRT without the context of why mood symptoms were occurring. They have often been managed, but not investigated.

The assessment I run is built on the understanding that perimenopausal mood disruption is a multi-system presentation, not a single-diagnosis problem.

It includes hormone assessment that goes beyond a one-off blood draw: DUTCH hormone testing captures estrogen metabolites, progesterone and its metabolites, DHEA, and the cortisol rhythm and awakening response across the day, giving a functional picture of where the hormonal system is sitting rather than a snapshot of one moment. It includes thyroid assessment, because thyroid dysfunction is common in perimenopausal women and produces mood symptoms that are indistinguishable from hormonal or psychiatric depression. It includes the nutritional markers described above: active B12, active folate (5-MTHF), vitamin D, ferritin, zinc, and magnesium. It includes metabolic assessment: fasting insulin, HOMA-IR, lipid panel, and inflammatory markers. It includes genetic screening for the variants described in this article. And where gut symptoms accompany the mood picture (as they frequently do, given the gut-brain connections discussed across multiple articles on this site), advanced microbiome screening and intestinal permeability assessment are added.

This is not a boutique workup. It is the investigation that the symptom picture warrants. And the interventions that follow from it, nutritional, hormonal, metabolic, and lifestyle, address the actual drivers of the mood disruption in a way that a single antidepressant, prescribed without this context, cannot.

Perimenopause is not a psychiatric event. It is a biological transition of extraordinary neurological complexity, occurring in women who are frequently at the peak of their responsibilities and the lowest point of their clinical support. They deserve an investigation, not just a prescription.

This post is for educational purposes only and does not constitute medical advice. If you are experiencing thoughts of harming yourself or others, please contact a mental health professional, your GP, or Lifeline on 13 11 14 immediately. This information is not a substitute for personalised clinical assessment.

Krystle Alves is a naturopath, nutritionist and yoga therapist with over 17 years of clinical experience. She works with a comprehensive, investigative approach. Consultations are available via telehealth Australia-wide. Book a consultation